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INTRODUCTION
During the past decade, our understanding of community
respiratory virus (CRV) infections in immunocompromised
adults, including bone marrow transplant (BMT) recipients
and patients undergoing intensive therapy for leukemia, has
greatly expanded. Prior to the early 1990s, the impact of
CRV-related complications in this population was largely
underestimated. In 2001, as the result of studies at M.D.
Anderson Cancer Center (MDACC) and elsewhere, it is
understood that CRV infections, which rarely cause compli-
cations in healthy adults, can cause substantial morbidity and
mortality among immunocompromised adults. As our under-
standing has grown, our approach to diagnosis and manage-
ment of these infections has changed substantially. The
results of a decade of studies of CRV infection in immuno-
compromised adults at MDACC are summarized here. 
EPIDEMIOLOGY OF CRV INFECTION IN
IMMUNOCOMPROMISED ADULTS 
There are notable center-to-center differences in the inci-
dence of CRV infections in immunocompromised adult
patients. These differences depend, in part, on the infection
rates in the surrounding communities, but they are also inﬂu-
enced by the rigor with which diagnosis is pursued and by the
intensity of immunosuppressive treatment prior to infection
onset, which may affect the morbidity and mortality associated
with the infection. At MDACC, during the winter inﬂuenza
season, CRV infections are the cause of approximately 20% to
30% of the hospitalizations required for adult patients under-
going treatment for leukemia and adult BMT recipients.
In a surveillance study conducted at MDACC during
the 1992-to-1993 and 1993-to-1994 winter influenza sea-
sons, for example, culture-confirmed CRV infections
occurred in 21% of all adult BMT recipients, caused pneu-
monia in 12%, and were responsible for death in 6%. Allo-
geneic BMT recipients had a higher risk of infection than
did autologous BMT recipients (29% versus 16%). How-
ever, mortality—unlike that reported in the European
Group for Blood and Marrow Transplantation study (see
Ljungman, this supplement)—was similar in allogeneic and
autologous BMT recipients (7% and 6%, respectively),
because many autologous BMT recipients at MDACC also
received intensive therapy for leukemia or lymphoma. 
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During these 2 winter inﬂuenza seasons, CRV infections
became the leading cause of viral pneumonia and viral pneu-
monia mortality in hospitalized BMT recipients with an
acute respiratory illness, whereas CMV-related pneumonia
and pneumonia mortality diminished in importance. Of the
48 viral pneumonia cases, 39 were attributed to CRVs and
9 to CMV; 25 deaths occurred, with 20 being attributed to
CRV infections and 5 to CMV infections. Among adult
BMT recipients at MDACC today, CRV infection is a major
cause of death, second only to Aspergillus infection.
RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
Incidence and Mortality
In studies of respiratory syncytial virus (RSV) infections
in adult BMT recipients, the time at which RSV infection
occurs has been shown to be a major inﬂuence on the clinical
presentation as well as the outcome. In BMT recipients with
RSV infections that occur before engraftment, RSV infection
typically progresses from an upper respiratory tract infection
(URTI) to a lower respiratory tract infection (LRTI), includ-
ing pneumonia. Progression from a URTI to pneumonia is
much less frequent in BMT recipients after engraftment.
Among 46 patients at MDACC with RSV URTIs, pneumo-
nia developed in 16 (80%) of 20 patients infected before
engraftment but in only 7 (27%) of 26 patients after engraft-
ment. Mortality rates among patients with RSV pneumonia
were high no matter when infection occurred; pneumonia-
related death occurred in 10 (63%) of 16 and 4 (57%) of
7 patients in the preengraftment and postengraftment
groups, respectively. 
Death of BMT recipients with RSV infection is usually
related to the infection. Postmortem examinations generally
reveal RSV to be the dominant pathogen in the lungs of these
patients; only rarely are bacterial superinfections also present.
Early Versus Late Treatment
In evaluating the efﬁcacy of treatment of RSV infection
in BMT recipients, both the time after BMT and the time at
which treatment was initiated should be considered. Because
the risk of pneumonia is greater among preengraftment than
postengraftment patients and mortality is high once pneu-
monia develops, treatment should have the greatest beneﬁt
when initiated early in preengraftment BMT recipients with
RSV URTIs. 
The effect of BMT stage (preengraftment versus
postengraftment) and time of treatment initiation on mor-
tality due to RSV pneumonia in 23 adult BMT recipients at
MDACC are shown in Table 1. Early treatment was associ-
ated with 40% mortality among the preengraftment patients
and 33% mortality among the postengraftment patients. In
contrast, late or no treatment resulted in 100% mortality in
both groups. Early and late treatment had similar effects on
mortality in autologous and allogeneic BMT recipients. 
Available Therapies 
Aerosolized ribavirin has been approved in the United
States for the treatment of serious RSV LRTIs in young
children. There are no efﬁcacy data from controlled clinical
trials in immunocompromised adults, although 1 such trial
is currently enrolling patients (see Nichols, this supplement).
Conﬂicting results have been reported in several small open
trials, with the best results being obtained when therapy is
initiated early [1-4]. Similarly, monotherapy with intra-
venous immunoglobulin (IVIG) may modify RSV infec-
tions. RSV-IVIG or monoclonal RSV antibody has been
evaluated in children with RSV, but few studies have evalu-
ated its use in treating adults [4].
Aerosolized Ribavirin Plus Intravenous
Immunoglobulin
Many recent open treatment trials in immunocompro-
mised adults have used combination therapy with aerosolized
ribavirin and an IVIG preparation [4,5]. Since 1992, we at
MDACC have treated adult BMT recipients who have RSV
pneumonia with aerosolized ribavirin (6 g daily) in combina-
tion with 1 of several immunoglobulin preparations (standard
IVIG, “hot lots” of IVIG containing high concentrations of
RSV-neutralizing antibodies, monoclonal RSV antibodies,
and RSV-IVIG) [4-6]. Our experience to date is summa-
rized in Table 2. When therapy was initiated early, the mor-
tality rate was 28%, compared with 60% to 100% when
patients were not treated, were treated late, or were intoler-
ant of ribavirin.
MDACC APPROACH TO TREATMENT OF RSV INFECTION
Time of Infection
The current approach to treatment of RSV infection in
BMT recipients at MDACC depends on when the infection
occurs following transplantation. If RSV URTI occurs
within 1 month of transplantation, aerosolized ribavirin and
Table 1. Factors Inﬂuencing Mortality in RSV Pneumonia in 23 Adult
BMT Recipients at MDACC
Late or No
Early Treatment, Treatment,
Factor Died/Treated, n (%) Died/Treated, n (%)
Autologous BMT (n = 12) 3/7 (43) 5/5 (100)
Allogeneic BMT (n = 11) 2/7 (29) 4/4 (100)
Preengraftment (n = 8) 2/5 (40) 3/3 (100)
Postengraftment (n = 15) 3/9 (33) 6/6 (100)
Table 2. Mortality Associated With RSV Pneumonia in Adult BMT 
Recipients Treated With Aerosolized Ribavirin and IVIG: MDACC, 
Winters, 1992-1993 to 1999-2000
No. of Patients Associated
Time of Therapy With Pneumonia Mortality, %
All 66 44
Early (all immunoglobulins) 46 28
Standard IVIG 27 22
“Hot lots” 13 31
Monoclonal RSV antibody 3 33
RSV-IVIG 3 67
Late 9 100
None 10 60
Ribavirin intolerance 1 100
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IVIG are initiated promptly to prevent progression to pneu-
monia. If RSV infection occurs more than 1 month after
transplantation, the decision about appropriate therapy is
based on clinical judgment. The patient’s overall condition,
concurrent therapy, and many other factors must be consid-
ered. If the RSV infection appears to be progressing, treat-
ment should be initiated. If the patient is stable, he or she
may be closely monitored without treatment. 
Infection Control Strategy
The most important factor in limiting RSV mortality in
BMT recipients is the recognition that infections caused by
CRVs, including RSV, are common and contagious. At
MDACC, patients are rigorously screened for CRV infec-
tions before transplantation. If symptoms are present, even
if culture and rapid detection tests are negative for RSV,
transplantation is delayed until the symptoms have resolved.
Education about CRV infections is offered to patients, their
families, and staff members. Patients are encouraged to wash
their hands frequently and to take other precautions to avoid
contamination with respiratory secretions. Only immediate
family members are allowed to visit the patient, and they are
urged to take the same precautions. Staff and visitors wear
masks and gloves when entering patients’ rooms. Staff mem-
bers with respiratory infections are instructed to avoid patient
contact while they are symptomatic. The time patients spend
in crowded areas with a high potential for infection exposure
should be limited; patients wear masks and gloves when they
are in high-risk areas. Finally, rigorous efforts are made to
identify, isolate, and treat BMT patients with respiratory
infections. Since infection control procedures were initiated
at MDACC, the incidence of nosocomial RSV infections
among BMT recipients has declined dramatically [7].
CONCLUSIONS
CRV infections are common among BMT recipients
during outbreaks of infection in the community. BMT
recipients in the preengraftment phase are at high risk for
progression of URTI to LRTI . RSV pneumonia may be
lethal at any time after BMT. Treatment with ribavirin and
immunoglobulin early in the course of an RSV infection
(before progression to pneumonia) appears to reduce mor-
tality, but the efficacy of this regimen has not been con-
firmed in a controlled clinical trial. Because no available
therapy has a reliable impact on mortality due to CRV
pneumonia, prevention of infection is crucial. Aggressive
infection control precautions can reduce nosocomial trans-
mission of CRV infections. 
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